In Vivo Assessment of the Safety of Standard Fractionation Temporally Feathered Radiation Therapy (TFRT) for Head and Neck Squamous Cell Carcinoma: An R-IDEAL Stage 1/2a First-in-Humans/Feasibility Demonstration of New Technology Implementation.

@article{Parsai2021InVA,
  title={In Vivo Assessment of the Safety of Standard Fractionation Temporally Feathered Radiation Therapy (TFRT) for Head and Neck Squamous Cell Carcinoma: An R-IDEAL Stage 1/2a First-in-Humans/Feasibility Demonstration of New Technology Implementation.},
  author={Shireen Parsai and Richard Lei J Qiu and Peng Qi and Geoffrey Sedor and Clifton David Fuller and Eric Murray and David Majkszak and Nicole Dorio and Shlomo A. Koyfman and Neil M. Woody and Nikhil P. Joshi and Jacob G. Scott},
  journal={Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology},
  year={2021}
}
2 Citations
Clinical implementation and initial experience with a 1.5 Tesla MR-linac for MR-guided radiotherapy for gynecologic cancer: An R-IDEAL stage 1/2a first in humans/feasibility study of new technology implementation
TLDR
The early clinical experience using an MR-linac for adaptive radiotherapy of gynecologic malignancies shows that the system is a reliable and clinically feasible tool for treating patients with Gynecologic cancer.

References

SHOWING 1-10 OF 15 REFERENCES
Technical Note: A step‐by‐step guide to Temporally Feathered Radiation Therapy planning for head and neck cancer
TLDR
A step‐by‐step guide to TFRT planning with modern treatment planning systems is demonstrated and Modest dosimetric changes are observed with T FRT planning compared with non‐TFRT IMRT planning.
Temporally feathered intensity‐modulated radiation therapy: A planning technique to reduce normal tissue toxicity
TLDR
TFRT is a novel technique for treatment planning and optimization of therapeutic radiotherapy that considers the nonlinear aspects of normal tissue repair to optimize toxicity profiles, and demonstrates potential for reduced normal tissue toxicity compared to conventionally planned IMRT.
Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer.
  • A. Forastiere, Q. Zhang, J. Cooper
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2013
TLDR
These 10-year results show that induction PF followed by RT and concomitant cisplatin/RT show similar efficacy for the composite end point of LFS, and new strategies that improve organ preservation and function with less morbidity are needed.
Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer.
  • C. Mcginn, M. Zalupski, T. Lawrence
  • Medicine, Physics
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2001
TLDR
A phase II trial of this novel gemcitabine-based chemoradiotherapy approach, at a radiation dose of 36 Gy in 2.4-Gy fractions, is recommended on the basis of tolerance, patterns of failure, and survival data.
Modern Image-Guided Intensity-Modulated Radiotherapy for Oropharynx Cancer and Severe Late Toxic Effects: Implications for Clinical Trial Design.
TLDR
The results suggest that severe late toxic effects after modern definitive IG-IMRT, with or without cisplatin, for oropharynx cancer is likely uncommon and the importance of late toxic effect reduction in current and future investigational strategies, including clinical trials, should be considered.
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
TLDR
The addition of concurrent high-dose, single-agent cisplatin to conventional single daily fractionated radiation significantly improves survival, although it also increases toxicity.
Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.
  • M. al-Sarraf, M. Leblanc, J. Ensley
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1998
TLDR
It is concluded that chemoradiotherapy is superior to radiotherapy alone for patients with advanced nasopharyngeal cancers with respect to PFS and overall survival.
...
...